39.5 F
New York
Wednesday, December 2, 2020

Why Biogen Inc [NASDAQ: BIIB] Stock Is Jumping?

Must read

Vodafone [NASDAQ: VOD] and RingCentral signs a partnership to provide next-generation services

Vodafone signed a strategic alliance with Ring Central . The association will modify business connections and alliances. The enterprises have joined hands to...

Salesforce [NYSE: CRM] Enters A Deal To Acquire Slack

Salesforce engages in a contract to buy Slack at a worth of $27.7B. This purchase to build an operating system for the...

Xilinx [NASDAQ: XLNX] Announced That It Acquired Falcon Computing

Xilinx Inc. declared that it has purchased falcon Computing Solutions to make flexible computing more accessible and easily adapted by computer programmers. The...

Luokung Corp. [NASDAQ: LKCO] To Acquire EMG For RMB 836 Million

Luokung Technologies Corp. a location-based service company has agreed to buy EMG technologies for Ren Min Bi  836 million. The company will pay...

Shares of Biogen Inc. [NASDAQ: BIIB] rocketed 43.97% as the company gained 43.97% on the trading session of Wednesday. It was reported that the Alzheimer drug of the company will soon receive the approval of the US Food and Drug Administration (FDA).

FDA Panel has found enough evidence to support the Alzheimer’s drug of the company. The independent committee of the FDA’s expert will assess the efficacy of a drug on Friday. Committee will give suggestions to the agency about the approval of the drug.

Shares of Biogen Inc. [NASDAQ: BIIB] jumped 43.97% as the company gained 108.62% during the trading session of Wednesday. It had a trading volume of 14.59 million as compared to the average volume of 1.40 million.

In the past 52-weeks of trading, this company’s stock has fluctuated between the 52-weeks low range of $243.25 and a high range of 374.99.

Turning our focus on its liquidity, it has a current ratio of 2.10 and a quick ratio of 1.80. Furthermore, this company has a total market capitalization of 53.29 billion at the time of writing.

Aducanumab is an antibody that is developed to remove amyloid plaques from the brain. The drug analyzer of the FDA commented that the one trial of Aducanumab showed promising results.

Nearly 6 million and millions of people around the globe are experiencing this disease. Biogen Inc. revealed that it has projected that 1.5 million people are the candidates for this drug.

More articles

Latest article

Nokia [NYSE: NOK] Extends Collaboration With AT&T to Deliver Seamless IoT Connectivity

Nokia Corp. declared that the company has extended its contract with AT&T . The collaboration among the companies can supply and provide an...

Wendy [NASDAQ: WEN] Strikes A Deal With Rebel Foods To Open 250 Cloud Kitchens.

Wendy’s Co. and Rebel foods have partnered to open about 250 cloud kitchens in India. These kitchens will only serve the customer with...

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...

Athene Enters Into An Agreement With Hertz To Buy Donlen Corp.

Athene Holdings ltd. entered into a deal to buy Donlen corporation from Hertz Global Holdings Inc. Hertz's fully own Donlen Corporation. The stock...

Verizon [NYSE: VZ] Announced to acquire Tracfone for $6.25 billion.

Verizon Communication Inc. declared that it penned down a deal with America Movil to purchase Tracfone for $6.25B. The companies came to terms...

ViacomCBS [NASDAQ: VIAC] Agreed To Sell Simon And Schuster For $2.175 Billion In Cash

ViacomCBS Inc. declared that it entered into an agreement with Penguin Random House LCC to sell Simon and Schuster. It will be sold...

IBM [NYSE: IBM] Plans To Cut Down 20% Of Its Workforce

International business machines Corp. declared that the company is preparing to cut down 10,000 jobs in Europe which makes it’s 20% of the...